TYRA

SEC source: 0000950170-25-088602 · ownership.xml · nonDerivative · entry 2

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,231

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.55 to $9.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0000950170-25-088602 · ownership.xml · nonDerivative · entry 1

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,799

SEC source: 0001415889-25-017446 · form4-06172025_120645.xml · nonDerivative · entry 3

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,259,291

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.12 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-086960 · ownership.xml · nonDerivative · entry 3

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,809

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.35 to $10.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001415889-25-017446 · form4-06172025_120645.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,247,478

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.09 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-086960 · ownership.xml · nonDerivative · entry 2

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,623

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001415889-25-017446 · form4-06172025_120645.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,127,311

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.17 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-086960 · ownership.xml · nonDerivative · entry 1

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,623

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001415889-25-016759 · form4-06112025_110646.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 10,096,004

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.14 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-25-015998 · form4-06062025_080635.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 9,909,154

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001415889-25-015998 · form4-06062025_080635.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 9,695,820

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.32 to $10.15 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-080227 · ownership.xml · derivative · entry 1

Rothenberg Stephen Michael · CIK 0002022747 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-080231 · ownership.xml · derivative · entry 1

Simson Jake · CIK 0001863094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

SEC source: 0001415889-25-015139 · form4-06022025_080640.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-25-080232 · ownership.xml · derivative · entry 1

Verjee Rehan · CIK 0001880637 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-080230 · ownership.xml · derivative · entry 1

MORE ROBERT J · CIK 0001207792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-080228 · ownership.xml · derivative · entry 1

Moran Susan · CIK 0001835225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-080226 · ownership.xml · derivative · entry 1

KAPLAN GILLA · CIK 0001247024 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,200

Underlying: Common Stock · 22,200 shares

Expires 2035-05-28

F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-041551 · ownership.xml · nonDerivative · entry 1

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,357,168

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0000950170-25-041550 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,087

F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0000950170-25-016385 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 443,885

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 ("Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-016385 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P

Disclosed balance after: 3,700,705

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-011737 · ownership.xml · derivative · entry 1

Gulfo Adele M. · CIK 0001647102 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,200

Underlying: Common Stock · 37,200 shares

Expires 2035-01-28

F1 · derivative.exercise_date: 1/36th of the total number of shares of common stock subject to the option vest monthly following January 29, 2025, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000950170-25-009278 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P

Disclosed balance after: 3,702,595

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 5

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P

Disclosed balance after: 3,707,420

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 4

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 447,396

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 3

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,711,413

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 447,857

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-25-007426 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,724,221

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-131084 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 448,692

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-131084 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,731,165

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0001415889-24-026718 · form4-11132024_051102.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 8,697,956

F1 · ownership.nature: These securities are held directly by the RA Capital Healthcare Fund, L.P. (the "Fund").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 4

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 449,258

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 3

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,735,871

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 451,629

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-124184 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,755,591

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 4

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 457,264

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 3

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,802,447

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 458,390

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-122639 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,811,814

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 8

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 458,506

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 7

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 458,579

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 6

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,812,774

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 5

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,813,378

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 4

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 461,457

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 3

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,837,316

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120099 · ownership.xml · nonDerivative · entry 1

Fuhrman Alan · CIK 0001303521 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,849

F1 · price: Represents the weighted average price for the entire number of shares purchased. The actual prices range between $15.95 to $16.00. Detailed information on the exact number of shares purchased at each price can be obtained from the Issuer upon request.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 2

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By 2020+ Co-Investment L.P. - Series 7

Disclosed balance after: 472,207

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-120198 · ownership.xml · nonDerivative · entry 1

Kjellson Nina S · CIK 0001381980 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Canaan XI L.P.

Disclosed balance after: 3,926,706

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.

SEC source: 0000950170-24-116345 · ownership.xml · nonDerivative · entry 3

Harris Todd · CIK 0001711463 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,355,927

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.8957 to $28.5951. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.